https://www.selleckchem.com/pr....oducts/danicamtiv-my
The NKG2C-KE triggered iNK cell-mediated cytotoxicity against CD33+ cells and primary AML blasts. The NKG2C-KE specific interaction with adaptive NK and NKG2C+ iNK cells represents a new immunotherapeutic paradigm that uniquely engages highly active NK cells to induce cytotoxicity against AML through redirected targeting.Hematopoietic stem cell gene therapy is emerging as a promising therapeutic strategy for many diseases of the blood and immune system. However, several patients that underwent gene therapy in different trials
Curtir
Comentario
Compartilhar
